Research Analysts Issue Forecasts for PRQR FY2026 Earnings

ProQR Therapeutics (NASDAQ:PRQR - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 EPS estimates for ProQR Therapeutics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the biopharmaceutical company will post earnings of ($0.50) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $8.00 price target on the stock. The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.31) per share.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The firm had revenue of $4.89 million during the quarter, compared to analysts' expectations of $4.90 million. ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%.

Several other analysts also recently commented on the stock. Chardan Capital reiterated a "buy" rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research report on Friday, March 14th. Evercore ISI assumed coverage on shares of ProQR Therapeutics in a research note on Tuesday, April 29th. They set an "outperform" rating and a $5.00 target price for the company. HC Wainwright raised their price target on ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Friday, March 14th. Citigroup raised ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective for the company in a research note on Monday, March 10th. Finally, Oppenheimer decreased their price objective on ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, ProQR Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $8.00.

ProQR Therapeutics Stock Performance

NASDAQ PRQR traded down $0.06 on Tuesday, reaching $1.88. The stock had a trading volume of 306,914 shares, compared to its average volume of 641,522. The stock has a market cap of $197.80 million, a P/E ratio of -5.88 and a beta of 0.31. ProQR Therapeutics has a 12-month low of $1.07 and a 12-month high of $4.62. The business's 50-day moving average price is $1.56 and its 200 day moving average price is $2.09.

Institutional Investors Weigh In On ProQR Therapeutics

A number of hedge funds have recently added to or reduced their stakes in PRQR. Jane Street Group LLC increased its position in ProQR Therapeutics by 699.3% during the 1st quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company's stock worth $121,000 after purchasing an additional 79,720 shares during the period. Affinity Asset Advisors LLC grew its holdings in ProQR Therapeutics by 16.3% during the first quarter. Affinity Asset Advisors LLC now owns 3,284,512 shares of the biopharmaceutical company's stock worth $4,368,000 after acquiring an additional 459,512 shares during the period. Walleye Capital LLC grew its holdings in ProQR Therapeutics by 11.6% during the first quarter. Walleye Capital LLC now owns 503,564 shares of the biopharmaceutical company's stock worth $670,000 after acquiring an additional 52,261 shares during the period. Aberdeen Group plc purchased a new position in ProQR Therapeutics in the first quarter worth $2,461,000. Finally, Persistent Asset Partners Ltd acquired a new stake in ProQR Therapeutics in the first quarter valued at $64,000. Institutional investors and hedge funds own 32.65% of the company's stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).